Intelligent Bio Solutions (INBS, Financial) is set to feature at the All Rise Conference, RISE25, occurring in Kissimmee, Florida, from May 28 to 31, 2025. The company plans to collaborate with its U.S. distribution partner, SMARTOX, to highlight the innovative capabilities of INBS’ fingerprint drug testing solution. Already employed in the U.S. for forensic purposes through SMARTOX, this portable system provides a rapid, hygienic method for drug detection.
Key figures such as Harry Simeonidis, President and CEO of INBS, and Doug Heath, Vice President of Global Sales, will be present alongside Duffy Nabors, Vice President of Sales and Marketing at SMARTOX, to present this cutting-edge technology. The fingerprint-based system is designed to detect recent consumption of drugs like cannabis (THC), cocaine, methamphetamine, and opiates, delivering results in under ten minutes. Its discreet and sanitary method is particularly useful for treatment court settings, probation programs, and other areas of the criminal justice system, where privacy, accuracy, and efficiency are essential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Intelligent Bio Solutions Inc (INBS, Financial) is $12.00 with a high estimate of $12.00 and a low estimate of $12.00. The average target implies an upside of 856.18% from the current price of $1.26. More detailed estimate data can be found on the Intelligent Bio Solutions Inc (INBS) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Intelligent Bio Solutions Inc's (INBS, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
